| __timestamp | Apellis Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 4733600000 |
| Thursday, January 1, 2015 | 13730311 | 4796400000 |
| Friday, January 1, 2016 | 22978599 | 5243900000 |
| Sunday, January 1, 2017 | 40303878 | 5281800000 |
| Monday, January 1, 2018 | 105285576 | 5051200000 |
| Tuesday, January 1, 2019 | 220968770 | 5595000000 |
| Wednesday, January 1, 2020 | 299921000 | 6085700000 |
| Friday, January 1, 2021 | 420869000 | 7025900000 |
| Saturday, January 1, 2022 | 387236000 | 7190800000 |
| Sunday, January 1, 2023 | 354387000 | 9313400000 |
| Monday, January 1, 2024 | 14271000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Eli Lilly and Company and Apellis Pharmaceuticals, Inc. have demonstrated contrasting approaches to R&D investment.
Eli Lilly, a stalwart in the industry, has consistently allocated substantial resources to R&D, with expenditures growing from approximately $4.7 billion in 2014 to over $9.3 billion in 2023. This represents a nearly 100% increase, underscoring their dedication to pioneering new treatments.
Conversely, Apellis Pharmaceuticals, a relatively newer player, has shown a remarkable growth trajectory in R&D spending, increasing from around $8 million in 2014 to $354 million in 2023. This exponential growth highlights their aggressive push towards innovation, albeit from a smaller base.
These trends reflect the dynamic strategies of established versus emerging pharmaceutical companies in the race for medical breakthroughs.
Analyzing R&D Budgets: Eli Lilly and Company vs Zoetis Inc.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and BeiGene, Ltd.
R&D Insights: How Eli Lilly and Company and Verona Pharma plc Allocate Funds
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Eli Lilly and Company or Soleno Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and MiMedx Group, Inc.
Research and Development: Comparing Key Metrics for Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and MorphoSys AG
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs Catalyst Pharmaceuticals, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Analyzing R&D Budgets: Apellis Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.